SCHEMBL6691708

SCHEMBL6691708

NC(=O)c1cccc2c1c1c(O)cccc1n2Cc1c(Cl)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
XBP1 P17861 1/20 0.48
PLA2G2A P14555 3/20 0.44
ALDH1A1 P00352 4/20 0.42
HTT P42858 3/20 0.42
MAPK1 P28482 2/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
CYP3A4 P08684 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 5/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693243 0.87 ALDH1A1 (0.47) LMNAMEN1KMT2APLA2G2AALDH1A1
SCHEMBL6696674 0.84 MAPK8 (0.42) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL7056324 0.84 ALDH1A1 (0.51) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL5212989 0.84 PLA2G2A (0.58) MEN1KMT2APLA2G2AALDH1A1KDM4E
SCHEMBL6691177 0.84 TSHR (0.43) LMNAKMT2APLA2G2AALDH1A1HTT
SCHEMBL6690183 0.81 PLA2G2A (0.62) KMT2APLA2G2AALDH1A1CYP3A4CYP2C9
SCHEMBL28512641 0.81 PLA2G2A (0.48) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL2586844 0.80 LMNA (0.45) LMNAMEN1KMT2AXBP1PLA2G2A
SCHEMBL818097 0.80 PLA2G2A (0.65) PLA2G2A
SCHEMBL27563279 0.78 LMNA (0.43) LMNAMEN1KMT2AXBP1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed